We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+2.03%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$6.75B
AUM Growth
+$227M
Cap. Flow
+$450M
Cap. Flow %
6.66%
Top 10 Hldgs %
24.03%
Holding
181
New
21
Increased
67
Reduced
21
Closed
25

Top Buys

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$76.7M
2
ZYME icon
Zymeworks
ZYME
+$56.8M
3
ENTG icon
Entegris
ENTG
+$55.4M
4
TSM icon
TSMC
TSM
+$52.9M
5
CGEM icon
Cullinan Oncology
CGEM
+$49.2M

Top Sells

Rank Stock Value
1
ECL icon
Ecolab
ECL
+$49.8M
2
W icon
Wayfair
W
+$45.9M
3
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$41.8M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$23.8M
5
CRWD icon
CrowdStrike
CRWD
+$23.5M

Sector Composition

Rank Sector Weight
1 Healthcare 40.16%
2 Technology 26.2%
3 Industrials 11.22%
4 Consumer Discretionary 7.43%
5 Communication Services 4.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCXI
76
DELISTED
ChemoCentryx, Inc.
CCXI
$28.7M 0.43%
560,000
+173,000
+45% +$10.4M
SMAR
77
DELISTED
Smartsheet Inc.
SMAR
$27.9M 0.41%
437,000
– –
XPO icon
78
XPO
XPO
$23.4B
$27.1M 0.4%
636,107
– –
SWKS icon
79
Skyworks Solutions
SWKS
$9.4B
$27.1M 0.4%
147,547
-33,000
-18% -$5.74M
XENE icon
80
Xenon Pharmaceuticals
XENE
$6.2B
$26.7M 0.4%
1,490,000
+459,860
+45% +$7.79M
KROS icon
81
Keros Therapeutics
KROS
$202M
$26.3M 0.39%
427,414
+81,414
+24% +$5.16M
MPWR icon
82
Monolithic Power Systems
MPWR
$64.7B
$26.2M 0.39%
74,159
+1,300
+2% +$473K
ROL icon
83
Rollins
ROL
$18.5B
$25M 0.37%
727,500
– –
OKTA icon
84
Okta
OKTA
$24.4B
$23.8M 0.35%
108,000
– –
MDB icon
85
MongoDB
MDB
$26.2B
$23.8M 0.35%
88,980
– –
KALA icon
86
KALA BIO
KALA
$13.6M
$23.3M 0.34%
1,381
– –
RGEN icon
87
Repligen
RGEN
$7.03B
$23.1M 0.34%
119,000
– –
PHAT icon
88
Phathom Pharmaceuticals
PHAT
$720M
$22.5M 0.33%
600,000
– –
ADCT icon
89
ADC Therapeutics
ADCT
$141M
$22.3M 0.33%
914,739
-160,261
-15% -$4.64M
MRTX
90
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$22.2M 0.33%
129,471
– –
XNCR icon
91
Xencor
XNCR
$1.59B
$21.8M 0.32%
506,000
– –
SHC icon
92
Sotera Health
SHC
$5.09B
$21.7M 0.32%
870,000
– –
BYND icon
93
Beyond Meat
BYND
$286M
$19.9M 0.29%
+152,593
New +$22.4M
XLRN
94
DELISTED
Acceleron Pharma
XLRN
$19.4M 0.29%
142,900
– –
BFLY icon
95
Butterfly Network
BFLY
$2.14B
$18.8M 0.28%
1,118,000
– –
ISRG icon
96
Intuitive Surgical
ISRG
$126B
$18.5M 0.27%
75,000
– –
FRC
97
DELISTED
First Republic Bank
FRC
$16.5M 0.25%
99,200
+34,900
+54% +$5.65M
CRDF icon
98
Cardiff Oncology
CRDF
$66.2M
$16.5M 0.24%
+1,783,488
New +$21.7M
SPRY icon
99
ARS Pharmaceuticals
SPRY
$559M
$16.2M 0.24%
371,384
+29,911
+9% +$1.42M
MASS icon
100
908 Devices
MASS
$313M
$16.2M 0.24%
333,283
– –
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Eventide Asset Management held 181 positions worth $6.75B, up 3.5% from $6.52B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Eventide Asset Management deployed $450M of net new capital in Q1 2021, opening 21 new positions and adding to 67 existing holdings. Its largest new stake was Prometheus Biosciences, Inc. Common Stock: 3,714,032 shares worth $65.6M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 42% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Wayfair, an estimated $45.9M trimmed.

  • Eventide Asset Management's largest Q1 2021 buy was Prometheus Biosciences, Inc. Common Stock: 3,714,032 shares worth $65.6M.
  • Eventide Asset Management added most to Entegris in Q1 2021, an estimated $55.4M increase.
  • Eventide Asset Management's biggest Q1 2021 reduction was Wayfair, cutting an estimated $45.9M.
  • Eventide Asset Management fully exited Ecolab in Q1 2021, selling an estimated $49.8M.
  • Eventide Asset Management's ten largest holdings make up 24% of its $6.75B portfolio in Q1 2021.
  • Eventide Asset Management opened 21 new positions and closed 25 in Q1 2021.
  • Eventide Asset Management's portfolio value rose 3.5% quarter-over-quarter to $6.75B.

Based on Eventide Asset Management's 13F filing for Q1 2021, filed 14 May 2021.